GH SecretagoguesLimited ResearchResearch Only — Preclinical EvidenceA

IGF-1 DES

des(1-3)IGF-1 / Truncated IGF-1 · IGF-1 receptor (IGF1R) agonism with markedly reduced IGFBP sequestration; activates PI3K/Akt/mTOR and MAPK pathways for protein synthesis and cell proliferation; short free-peptide half-life favors brief, localized signaling rather than sustained systemic exposure

Last reviewed . First published . By the PeptIQ team.

Educational and observational reference only. Not medical advice. Community charts may use modeled aggregates when live snapshots are unavailable.

Studies cited
10
Research grade
A
Experience
70

Overall check-ins

Activity
68

Trackers & reports

Typical Dose

50–150 mcg daily in research discussions (often peri-workout); no established human dose

Route

Injectable (SubQ or IM)

Cycle

Short research cycles only; washouts recommended due to glucose effects

Storage

Lyophilized frozen; reconstituted 2–8°C, use within 2–4 weeks

What is IGF-1 DES?

IGF-1 DES (des(1-3)IGF-1) is a truncated 67-amino-acid analog of insulin-like growth factor-1 missing the N-terminal Gly-Pro-Glu tripeptide. Reduced IGF-binding protein affinity leaves more free peptide for IGF-1 receptor activation, yielding roughly 2–10× potency vs native IGF-1 in preclinical assays — but a very short ~20–30 minute half-life. Evidence is almost entirely animal/cell literature; not FDA-approved.

Mechanism of Action

IGF-1 receptor (IGF1R) agonism with markedly reduced IGFBP sequestration; activates PI3K/Akt/mTOR and MAPK pathways for protein synthesis and cell proliferation; short free-peptide half-life favors brief, localized signaling rather than sustained systemic exposure

Target: IGF-1 receptor (IGF1R); reduced IGFBP-1/IGFBP-3 binding

Research Indications

Growth Hormone SupportMost Effective

Stimulates natural GH release through pituitary signaling pathways

Body CompositionEffective

Associated with increased lean mass and reduced body fat

Recovery & RepairEffective

Supports tissue repair and recovery from exercise or injury

Sleep QualityModerate

Some protocols show improvements in slow-wave and restorative sleep

Research Protocols

These are commonly discussed research protocols — not medical advice. Consult a healthcare provider before use.

GoalDoseFrequencyRoute
Conservative Research Start50 mcgOnce daily (peri-workout)SubQ or IM
Common Research Range50–100 mcgOnce dailySubQ or IM
Upper Community Discussion100–150 mcgOnce daily, short cyclesSubQ or IM

Peptide & Drug Interactions

Always consult your healthcare provider before combining with other compounds. Use our Interaction Checker for reference.

Insulin / insulin secretagoguesAvoid
IGF-1 LR3 (redundant IGF-axis load)Caution
HGH / GH secretagoguesMonitor
PEG-MGFCaution
BPC-157Compatible
Blood glucose–lowering medicationsMonitor

How to Reconstitute & Inject

Use bacteriostatic (BAC) water only. Avoid saline — may cause precipitation. Refrigerate and use within 28 days.

  1. 1

    Remove IGF-1 DES vial from refrigeration and allow to reach room temperature (15–20 minutes)

  2. 2

    Clean vial top with alcohol swab and allow to air dry completely

  3. 3

    Using a sterile syringe, draw the calculated volume of bacteriostatic water (BAC water)

  4. 4

    Inject BAC water slowly down the side of the vial — do not aim directly at the powder

  5. 5

    Gently swirl in circular motions — DO NOT shake vigorously as this degrades the peptide

  6. 6

    Allow 2–3 minutes for full dissolution — solution should be clear and colorless

  7. 7

    Draw calculated dose into an insulin syringe for subcutaneous injection

  8. 8

    Inject into abdomen, thigh, or upper arm. Rotate injection sites to prevent lipodystrophy

  9. 9

    Store reconstituted solution refrigerated (2–8°C) and use within 28 days

What to Expect

Week 1–2

Improved sleep quality may begin. Mild water retention possible initially.

Week 2–4

Deeper sleep, improved recovery. Appetite may increase slightly.

Week 4–8

Noticeable improvements in body composition, energy, and recovery speed.

Week 8–12

Skin quality improvements, reduced body fat, increased lean mass becoming visible.

Week 12+

Sustained improvements in body composition, strength, and overall vitality.

Side Effects & Safety

  • Hypoglycemia — the primary preclinical safety signal for IGFBP-poor IGF variants; monitor blood glucose closely
  • Symptoms of low blood sugar (shakiness, sweating, confusion) especially peri-workout or when fasted
  • Injection site reactions (redness, bruising, discomfort)
  • Theoretical growth-pathway concerns from strong IGF-1 receptor activation
  • Risk of additive hypoglycemia when combined with insulin or other IGF-axis compounds — avoid casual stacking
  • Human safety is not established — research-only and not FDA-approved

FDA Status & Regulatory Info

Research Only — Preclinical Evidence

IGF-1 DES (des(1-3)IGF-1) is a truncated 67-amino-acid analog of insulin-like growth factor-1 missing the N-terminal Gly-Pro-Glu tripeptide. Reduced IGF-binding protein affinity leaves more free peptide for IGF-1 receptor activation, yielding roughly 2–10× potency vs native IGF-1 in preclinical assays — but a very short ~20–30 minute half-life. Evidence is almost entirely animal/cell literature; not FDA-approved.

Rx Required: No
503A Ban: No
Telehealth: N/A
Full FDA Status Tracker

Frequently Asked Questions

Community-reported data

The information below reflects self-reported experiences from PeptIQ app users. It is not clinical evidence and should not replace professional medical advice.

What 2,337 users report

Observational self-reports (modeled when live data is unavailable). Not clinical outcomes.

2337 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 51% · Mixed 32% · Unfavorable overall 17%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Skin appearance
48
Appetite control
39
Energy
127
Mood
93
Focus
112

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Headache
144
GI discomfort
118
Dizziness
92
Fatigue
89
Nausea
111

Self-reported dose per injection

Median bucket: 0.4–0.6 mg · Most common: 0.2–0.4 mg

Reports span 0.05–2 mg

0.05–0.1 mg
7
0.1–0.2 mg
15
0.2–0.4 mg
18
0.4–0.6 mg
14
0.6–1 mg
8
1–2 mg
2

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing21stacking19side effects17igf-1 des20

How repeat users are trending

Among repeat reporters, 61% said they felt similar to their last entry, 43% more positive, and 21% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 23 days · Based on 514 repeat reporters

Share Your Experience

Rate IGF-1 DES in the PeptIQ app and help the community make informed decisions.

Research References (6)

Cited PubMed, trial registry, and label sources for education only. We do not control third-party content.

  1. PubMed

    Des(1-3)IGF-I: a truncated form of insulin-like growth factor-I

    Ballard FJ, Wallace JC, Francis GL, et al. Int J Biochem Cell Biol. 1996

    Source
    Wiki study page →
  2. PubMed

    Enhanced potency of truncated insulin-like growth factor-I (des(1-3)IGF-I) relative to IGF-I in lit/lit mice

    Gillespie C, Read LC, Bagley CJ, et al. J Endocrinol. 1990

    Source
    Wiki study page →
  3. PubMed

    In vivo actions of IGF analogues with poor affinities for IGFBPs: metabolic and growth effects in pigs of different ages and GH responsiveness

    Walton PE, Dunshea FR, Ballard FJ. Prog Growth Factor Res. 1995

    Source
    Wiki study page →
  4. PubMed

    IGF-I variants which bind poorly to IGF-binding proteins show more potent and prolonged hypoglycaemic action than native IGF-I in pigs and marmoset monkeys

    Tomas FM, Walton PE, Dunshea FR, et al. J Endocrinol. 1997

    Source
    Wiki study page →
  5. PubMed

    Insulin-like growth factor-I and its N-terminal modified analogues induce marked gut growth in dexamethasone-treated rats

    Read LC, Tomas FM, Howarth GS, et al. J Endocrinol. 1992

    Source
    Wiki study page →
  6. ClinicalTrials.gov

    des(1-3)IGF-1 / IGF-1 DES studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →

Wiki tools

Observational indexes and compare views for IGF-1 DES.

Often tracked with

Educational information only

This page is for educational reference. It is not medical or legal advice. PeptIQ does not sell peptides or list vendors. Consult the FDA and a licensed healthcare professional for current regulations and individualized guidance.

PeptIQ app

Log your IGF-1 DES protocol in PeptIQ

Turn this IGF-1 DES guide into a living protocol — doses, vials, and history in one place.

Track IGF-1 DESOpen web app

iOS, Android, and web

Ask PeptIQ

Two taps on our guided quiz, then keep going in iMessage with sources — not Instagram screenshots.

Start the quizOr try Peptide X Quiz →

Quick Facts

Half-Life
~20-30 minutes
Target
IGF-1 receptor (IGF1R); reduced IGFBP-1/IGFBP-3 binding
Route
Injectable (SubQ or IM)
Availability
Research only
Rx Required
No
503A Ban
No
Browse peptide education

Talk with a clinician

PeptIQ is education only. We do not sell peptides or list vendors. Discuss IGF-1 DES with a licensed healthcare provider — not medical advice, not a prescription.

Download PeptIQ

Wiki tools

Observational indexes and compare views for IGF-1 DES.

Often tracked with